Abstract:As the world's first primary morbidity factor, depression has a considerable impact on both an individual as well as a societal level. despite their discovery several decades ago, classical antidepressants have been shown to provide limited benefits against this condition. However, substances such as ketamine and psychedelics have recently shown promising results and even received the grade of Breakthrough therapy for this indication. The accurate mechanisms of action underlying the efficacy of these substances are still to be defined, but some similarities appear to be shared on different levels across these substances. These include their structural, functional and behavioral plasticity promoting abilities, as well as their capacity to promote Brain-Derived Neurotrophic Factor overexpression, which seems to constitute a key element underlying their immediate and long-lasting action. From this observation, the present review aims to examine and connect the pharmacological pathways involved in these therapies to the neurobiological, cognitive and psychological responses that could be shared by both 5-HT2AR agonists and NMDA antagonists. It is suggested that BDNF overexpression resulting from mTOR activation mediates both structural and functional plasticity, resulting in connectivity changes among high-level cognitive networks such as the Default Mode Network, finally leading to an increased and long-lasting psychological flexibility. Connecting these pieces of evidence could provide insights about their precise mechanisms of action and help researchers to develop biomarkers for antidepressant response. If the hypotheses suggested in this review are verified by further trials, they could also constitute a starting point to developing safer and more efficient antidepressants, as well as provide information about the interactions that exist between different neurotransmitters systems.

Changes in Hippocampal Plasticity in Depression and Therapeutic Approaches Influencing These Changes

Neural Plasticity and Depression Treatment

Dysregulation of adult hippocampal neuroplasticity in major depression: pathogenesis and therapeutic implications

The therapeutic potential of traditional Chinese medicine in depression: focused on the modulation of neuroplasticity

Neuroplasticity and depression: Rewiring the brain's networks through pharmacological therapy (Review)

5-HT2A mediated plasticity as a target in major depression: a narrative review connecting the dots from neurobiology to cognition and psychology

Neuroplasticity: Pathophysiology and Role in Major Depressive Disorder

Applications of Acupuncture Therapy in Modulating the Plasticity of Neurodegenerative Disease and Depression: Do MicroRNA and Neurotrophin BDNF Shed Light on the Underlying Mechanism?

Prospective Role of MicroRNAs in Depression

Synaptic plasticity in depression: molecular, cellular and functional correlates

Progress in the "Brain-Derived Neurotrophic Factor Hypothesis of Depression"

Neuroplasticity and the Biological Role of Brain Derived Neurotrophic Factor in the Pathophysiology and Management of Depression

[Traditional Chinese medicine prevents and treats depression by regulating hippocampal neuroplasticity: a review]

From Perspective of Hippocampal Plasticity: Function of Antidepressant Chinese Medicine Xiaoyaosan

Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression

A new perspective on hippocampal synaptic plasticity and post‐stroke depression

New perspective on sustained antidepressant effect: focus on neurexins regulating synaptic plasticity

Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression

A New Player in Depression: MiRNAs as Modulators of Altered Synaptic Plasticity

Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression

New advances in therapeutic targets for antidepressants